The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3369-3378

  Douglas, Mark ^a   Lim, Alice R ^a   Porter, James R ^a   West, Kip ^a   Pink, Melissa M ^a   Ge, Jie ^a   Wylie, Andrew A ^a   Tibbits, Thomas T ^a   Biggs, Kurtis ^a   Curtis, Michael ^a   Palombella, Vito J ^a   Adams, Julian ^a   Fritz, Christian C ^a   Normant, Emmanuel ^a  

^a Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 AMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; DRUG METABOLITE; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROQUINONE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ACTIVITY; CELL LEVEL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RECEPTOR BINDING; DRUG SCREENING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; HYDROQUINONES; IMMUNOBLOTTING; K562 CELLS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, NUDE; MUTATION; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; PROTEIN BINDING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73149098932     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0568     Document Type: Article

References (42)

1. Workman P, De Billy E. Putting the heat on cancer. Nat Med 2007;13: 1415-7.
2. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-30.
3. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021-30.
4. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
5. McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 2003;8:303-8.
6. Bagatell R, Khan O, Paine-Murrieta G, et al. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84.
7. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004;15:377-87.
8. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/ hypoxia-inducible factor-1á autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13:6459-68.
9. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100.
10. Peng C, Brain J, Hu Y, et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007;110:678-85.
11. Sawai A, Chandarlapaty S, Greulich H, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008;68:589-96.
12. Shimamura T, Li D, Ji H, Haringsma HJ. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008;68:5827-38.
13. Ge J, Normant E, Porter JR, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49:4606-15.
14. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103:17408-13.
15. Guo W, Reigan P, Siegel D, et al. Formation of 17- allylaminodemethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15.
16. Demetri GD, Morgan J, Wagner A, et al. Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI 504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: updated results of a phase I trial. in ASCO Annual Meeting 2007.
17. Kefford R, Millward M, Hersey B, et al. Phase II trial of tanespimycin (KOS 953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. in ASCO annual meeting. 2007.
18. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumabrefractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7.
19. Sequist L, Sweeney J, Grayzel D,Walker S, Lynch T. Phase 1/2 trial of a novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer stratified by EGFR mutation status. in AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2007.
20. Sequist L, Gettinger S, Natale R, et al. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. J Clin Oncol 2009;27:837-8.
21. Maroney AC, Marugan JJ, Mezzasalma TM, et al. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 2006;45:5678-85.
22. Onuoha SC, Mukund SR, Coulstock ET, et al. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 2007;372:287-97.
23. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DTDiaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
24. Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75.
25. Brunton VG, Steele G, Lewis AD, Workman P. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase. Cancer Chemother Pharmacol 1998;41: 417-22.
26. Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett 2003;13:3975-8.
27. Patterson J, Palombella VJ, Fritz C, Normant E. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 2008;61:923-32.
28. Fitzsimmons SA, Workman P, Grever M, et al. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-69.
29. Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1. Mol Pharmacol 2008;74:1657-65.
30. Winski SL, Swann E, Hargreaves RH, et al. Relationship between NAD (P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001;61:1509-16.
31. Seow HA, Penketh PG, Belcourt MF, et al. Nuclear overexpression of NAD(P)H:quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions. J Biol Chem 2004;279:31606-12.
32. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997;76:852-4.
33. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helixloop-helix transcription factors. Mutat Res 2004;555:149-71.
34. Siegel D, Anwar A, Winski SL, et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-8.
35. Tudor G, Alley M, Nelson CM, et al. Cytotoxicity of RH1: NAD(P)H: quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction. Anticancer Drugs 2005;16:381-91.
36. Lang W, Caldwell GW, Li J, et al. Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos 2007;35:21-9.
37. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002;100:3041-4.
38. Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002;16:1535-40.
39. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60.
40. Okawa Y, Hideshima T, Steed P, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009;113:846-55.
41. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
42. Goetz S, Toft D, Reid S, Adams S. A phase I trial of 17-allyl- aminogeldanamycin (17-AAG) in patients with advanced cancer. Eur J Cancer 2002;38.